PDP2

Summary

PDP2 (pyruvate dehydrogenase phosphatase catalytic subunit 2, HGNC:30263) is a protein-coding gene on chromosome 16q22.1, encoding [Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 2, mitochondrial (Q9P2J9). Mitochondrial enzyme that catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex (PDC), thereby stimulating the conversion of pyruvate into acetyl-CoA.

This gene is a mitochondrial protein that functions as a phosphatase and is involved in the enzymatic resetting of the pyruvate dehydrogenase complex. Alternative splicing results in multiple transcript variants encoding the same protein.

Source: NCBI Gene 57546 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 84 total
• MANE Select transcript: NM_020786

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30263
Approved symbol	PDP2
Name	pyruvate dehydrogenase phosphatase catalytic subunit 2
Location	16q22.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1348, PPM2C2, PPM2B
Ensembl gene	ENSG00000172840
Ensembl biotype	protein_coding
OMIM	615499
Entrez	57546

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 19 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000311765, ENST00000561475, ENST00000561704, ENST00000566543, ENST00000566776, ENST00000566805, ENST00000568398, ENST00000568720, ENST00000568869, ENST00000853885, ENST00000853886, ENST00000853887, ENST00000926811, ENST00000926812, ENST00000926813, ENST00000926814, ENST00000926815, ENST00000941564, ENST00000941565, ENST00000941566, ENST00000941567, ENST00000941568

RefSeq mRNA: 8 — MANE Select: NM_020786 NM_001329928, NM_001329929, NM_001329930, NM_001329931, NM_001329932, NM_001329933, NM_001329934, NM_020786

CCDS: CCDS10822

Canonical transcript exons

ENST00000311765 — 2 exons

Exon	Start	End
ENSE00001207017	66884231	66891101
ENSE00002585390	66880515	66880640

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 83.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.7835 / max 82.8623, expressed in 1707 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154533	9.7835	1707

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	83.81	gold quality
epithelial cell of pancreas	CL:0000083	80.85	silver quality
calcaneal tendon	UBERON:0003701	80.37	gold quality
stromal cell of endometrium	CL:0002255	79.47	gold quality
Brodmann (1909) area 23	UBERON:0013554	79.18	gold quality
islet of Langerhans	UBERON:0000006	78.51	gold quality
middle temporal gyrus	UBERON:0002771	78.37	gold quality
ventricular zone	UBERON:0003053	78.35	gold quality
secondary oocyte	CL:0000655	78.11	gold quality
adrenal tissue	UBERON:0018303	78.10	gold quality
primary visual cortex	UBERON:0002436	77.58	gold quality
adult mammalian kidney	UBERON:0000082	77.36	gold quality
colonic epithelium	UBERON:0000397	76.98	gold quality
embryo	UBERON:0000922	76.75	gold quality
ganglionic eminence	UBERON:0004023	76.75	gold quality
corpus callosum	UBERON:0002336	76.60	gold quality
cortical plate	UBERON:0005343	76.57	gold quality
kidney	UBERON:0002113	76.17	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.02	gold quality
cortex of kidney	UBERON:0001225	76.02	gold quality
prefrontal cortex	UBERON:0000451	75.99	gold quality
adipose tissue	UBERON:0001013	75.62	gold quality
renal medulla	UBERON:0000362	75.36	gold quality
rectum	UBERON:0001052	75.32	gold quality
right lobe of liver	UBERON:0001114	75.13	gold quality
right coronary artery	UBERON:0001625	75.03	gold quality
pancreas	UBERON:0001264	74.96	gold quality
subcutaneous adipose tissue	UBERON:0002190	74.96	gold quality
liver	UBERON:0002107	74.69	gold quality
right lung	UBERON:0002167	74.67	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.14
E-GEOD-99795	no	45.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

196 targeting PDP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-373-5P	99.98	75.36	4753
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7G-5P	99.98	72.37	1784
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650

Literature-anchored findings (GeneRIF, showing 3)

• catalytic subunit of PDP2 crystals belonged to space group P2(1)2(1)2(1), with unit-cell parameters a = 53.6, b = 69.1, c = 109.7 A. (PMID:20208177)
• ICER was found to bind to the Pdp2 promoter and suppress its expression. Furthermore, forced expression of PDP2 in CD4(+) cells reduced the in vitro Th17 differentiation, whereas shRNA-based suppression of PDP2 expression increased in vitro Th17 differentiation (PMID:30150402)
• Autocrine phosphatase PDP2 inhibits ferroptosis by dephosphorylating ACSL4 in the Luminal A Breast Cancer. (PMID:38466744)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	pdp2	ENSDARG00000058571
mus_musculus	Pdp2	ENSMUSG00000048371
rattus_norvegicus	Pdp2	ENSRNOG00000012343
drosophila_melanogaster	Pdp	FBGN0029958
drosophila_melanogaster	CG10376	FBGN0032702
drosophila_melanogaster	Ppm1	FBGN0035143
drosophila_melanogaster	CG17746	FBGN0035425
drosophila_melanogaster	Nil	FBGN0039421
drosophila_melanogaster	alph	FBGN0086361
caenorhabditis_elegans		WBGENE00006460
caenorhabditis_elegans		WBGENE00018362
caenorhabditis_elegans	pdp-1	WBGENE00022832

Paralogs (16): PPM1F (ENSG00000100034), TAB1 (ENSG00000100324), PPM1A (ENSG00000100614), PPM1H (ENSG00000111110), PPM1G (ENSG00000115241), ILKAP (ENSG00000132323), PPM1B (ENSG00000138032), PPM1J (ENSG00000155367), PPM1L (ENSG00000163590), PPM1K (ENSG00000163644), PPM1M (ENSG00000164088), PDP1 (ENSG00000164951), PPM1D (ENSG00000170836), PPM1E (ENSG00000175175), PP2D1 (ENSG00000183977), PPM1N (ENSG00000213889)

Protein

Protein identifiers

[Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 2, mitochondrial — Q9P2J9 (reviewed: Q9P2J9)

Alternative names: Pyruvate dehydrogenase phosphatase catalytic subunit 2

All UniProt accessions (6): Q9P2J9, H3BQX2, H3BRB7, H3BSA5, H3BTU5, H3BV50

UniProt curated annotations — full annotation on UniProt →

Function. Mitochondrial enzyme that catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex (PDC), thereby stimulating the conversion of pyruvate into acetyl-CoA. Acts as a crucial regulator of T cell metabolism and function, with a particular focus on T-helper Th17.

Subcellular location. Mitochondrion.

Cofactor. Binds 2 magnesium ions per subunit.

Similarity. Belongs to the PP2C family.

RefSeq proteins (8): NP_001316857, NP_001316858, NP_001316859, NP_001316860, NP_001316861, NP_001316862, NP_001316863, NP_065837* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000222	PP2C_BS	Binding_site
IPR001932	PPM-type_phosphatase-like_dom	Domain
IPR015655	PP2C	Family
IPR036457	PPM-type-like_dom_sf	Homologous_superfamily

Pfam: PF00481

Enzyme classification (BRENDA):

• EC 3.1.3.43 — [pyruvate dehydrogenase (acetyl-transferring)]-phosphatase (BRENDA: 11 organisms, 19 substrates, 32 inhibitors, 15 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

7 substrates with measured Km, best-characterized 7. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
[PYRUVATE DEHYDROGENASE (LIPOAMIDE)]-PHOSPHATE	0.0029–0.058	7
P-NITROPHENYL PHOSPHATE	29.3–55.1	3
PEPTIDE T-1	0.625	1
PEPTIDE T-2	0.22	1
PEPTIDE T-3	0.106	1
RRAS(P)VA	0.053	1
RRAT(P)VA	0.018	1

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-seryl-[pyruvate dehydrogenase E1 alpha subunit] + H2O = L-seryl-[pyruvate dehydrogenase E1 alpha subunit] + phosphate (RHEA:12669)

UniProt features (8 total): binding site 5, transit peptide 1, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P2J9-F1	81.79	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 141; 141; 142; 412; 508

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-204174	Regulation of pyruvate dehydrogenase (PDH) complex

MSigDB gene sets: 133 (showing top): RNGTGGGC_UNKNOWN, chr16q22, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_DN, DARWICHE_PAPILLOMA_RISK_HIGH_DN, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN, SREBP1_02, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_CD4_POSITIVE_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_T_CELL_DIFFERENTIATION_INVOLVED_IN_IMMUNE_RESPONSE, GARY_CD5_TARGETS_DN, HIF1_Q3, GOBP_ALPHA_BETA_T_CELL_ACTIVATION

GO Biological Process (2): T-helper cell differentiation (GO:0042093), protein dephosphorylation (GO:0006470)

GO Molecular Function (6): [pyruvate dehydrogenase (acetyl-transferring)]-phosphatase activity (GO:0004741), metal ion binding (GO:0046872), phosphoprotein phosphatase activity (GO:0004721), protein serine/threonine phosphatase activity (GO:0004722), hydrolase activity (GO:0016787), cation binding (GO:0043169)

GO Cellular Component (2): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Regulation of pyruvate metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
CD4-positive, alpha-beta T cell differentiation	1
dephosphorylation	1
protein modification process	1
protein serine/threonine phosphatase activity	1
cation binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
phosphoprotein phosphatase activity	1
catalytic activity	1
ion binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
mitochondrion	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1627 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PDP2	PDHX	O00330	970
PDP2	PDHB	P11177	904
PDP2	DLAT	P10515	878
PDP2	PDHA1	P08559	815
PDP2	DLD	P09622	714
PDP2	PDK3	Q15120	712
PDP2	PDK2	Q15119	706
PDP2	PDK4	Q16654	692
PDP2	PDPR	Q8NCN5	633
PDP2	PDK1	Q15118	572
PDP2	PPARGC1A	Q9UBK2	522
PDP2	DIRAS1	O95057	480
PDP2	IDH2	P48735	480
PDP2	LRCH1	Q9Y2L9	477
PDP2	LIPT2	A6NK58	467

IntAct

20 interactions, top by confidence:

A	B	Type	Score
GFAP	NEFL	psi-mi:“MI:0914”(association)	0.850
NDUFS7	NDUFS8	psi-mi:“MI:0914”(association)	0.640
SPINK2	STRN	psi-mi:“MI:0914”(association)	0.530
NPB	CST4	psi-mi:“MI:0914”(association)	0.530
NDUFS7		psi-mi:“MI:0914”(association)	0.350
NPB	IL16	psi-mi:“MI:0914”(association)	0.350
TMEM184A	NRDC	psi-mi:“MI:0914”(association)	0.350
ACP7	MYCBP2	psi-mi:“MI:0914”(association)	0.350
NOX5	TTC4	psi-mi:“MI:0914”(association)	0.350
PDP2	CLPX	psi-mi:“MI:0914”(association)	0.350
IBSP	METTL15	psi-mi:“MI:0914”(association)	0.350
SULF2	CCDC85C	psi-mi:“MI:0914”(association)	0.350
GLIS2	USO1	psi-mi:“MI:0914”(association)	0.350
NOX5	RNASEH2A	psi-mi:“MI:0914”(association)	0.350
SULF2	CENPB	psi-mi:“MI:0914”(association)	0.350
TRMT61B	VWA8	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (26): PDP2 (Affinity Capture-MS), AFG3L2 (Affinity Capture-MS), CLPX (Affinity Capture-MS), UBR2 (Affinity Capture-MS), YME1L1 (Affinity Capture-MS), PDP2 (Affinity Capture-MS), PDP2 (Affinity Capture-MS), PDP2 (Affinity Capture-MS), PDP2 (Affinity Capture-MS), PDP2 (Affinity Capture-MS), PDP2 (Affinity Capture-MS), PDP2 (Affinity Capture-MS), PDP2 (Proximity Label-MS), PDP2 (Affinity Capture-MS), PDP2 (Affinity Capture-Western)

ESM2 similar proteins: A5PJZ2, O81760, O88484, P40371, P49599, Q0DBU3, Q0IIF0, Q0V7V2, Q0WRB2, Q10MN6, Q10S32, Q2QN36, Q501F9, Q504M2, Q5JJY4, Q5JKN1, Q5MFV5, Q5PNS9, Q5SGD2, Q5SMK6, Q5Z8P0, Q653S3, Q67UP9, Q69VD9, Q6ETK3, Q6NKS1, Q6YTI2, Q6ZHC8, Q7XCJ7, Q7XUC5, Q7Y138, Q84JD5, Q8BHN0, Q8H063, Q8LAY8, Q940A2, Q942P9, Q94CL8, Q94H98, Q9FKX4

Diamond homologs: A0A7U2MSD6, A0BLX0, A3A8W2, F1LNI5, G0RT93, O14189, O15355, O62830, O75688, O88483, O88484, P35815, P35816, P49595, Q09172, Q09173, Q0J2L7, Q10S32, Q3UV70, Q4R4V2, Q4WTH5, Q501F9, Q504M2, Q5JJY4, Q5MFV5, Q5PNS9, Q5RA52, Q61074, Q652Z7, Q65XG6, Q84JD5, Q8H2T0, Q940A2, Q94CL8, Q94H98, Q9FKX4, Q9LNF4, Q9LNW3, Q9LUU7, Q9P0J1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PDP2	down-regulates	SMAD1	dephosphorylation
PDP2	“up-regulates activity”	PDHA1	dephosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

84 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	72
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

698 predictions. Top by Δscore:

Variant	Effect	Δscore
16:66885796:G:GT	donor_gain	0.9900
16:66885806:G:T	donor_gain	0.9900
16:66880637:GCTG:G	donor_gain	0.9700
16:66881248:G:GT	donor_gain	0.9400
16:66881403:TCA:T	donor_gain	0.9400
16:66885805:GGA:G	donor_gain	0.9300
16:66885826:G:GA	donor_gain	0.9300
16:66885867:GGGGT:G	donor_gain	0.9300
16:66881628:C:CG	donor_gain	0.9000
16:66884226:TTTA:T	acceptor_loss	0.9000
16:66884228:TAGGT:T	acceptor_loss	0.9000
16:66884229:A:G	acceptor_loss	0.9000
16:66884230:G:GT	acceptor_loss	0.9000
16:66885806:G:GT	donor_gain	0.9000
16:66881628:C:G	donor_gain	0.8900
16:66884222:A:AG	acceptor_loss	0.8900
16:66885729:A:AG	donor_gain	0.8700
16:66880636:AGCTG:A	donor_loss	0.8600
16:66880637:GCTGG:G	donor_loss	0.8600
16:66880639:TG:T	donor_loss	0.8600
16:66880640:GGT:G	donor_loss	0.8600
16:66880641:GTGAG:G	donor_loss	0.8600
16:66880642:T:G	donor_loss	0.8600
16:66880643:GA:G	donor_loss	0.8600
16:66880644:AGAAG:A	donor_loss	0.8500
16:66880645:G:C	donor_loss	0.8500
16:66885795:GGAT:G	donor_gain	0.8500
16:66885796:G:T	donor_gain	0.8500
16:66885856:A:G	donor_gain	0.8500
16:66880984:C:T	donor_gain	0.8300

AlphaMissense

3477 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:66885805:G:C	R507S	0.996
16:66885805:G:T	R507S	0.996
16:66885807:A:T	D508V	0.995
16:66885810:A:T	D509V	0.995
16:66885804:G:C	R507T	0.992
16:66885807:A:C	D508A	0.992
16:66885809:G:C	D509H	0.992
16:66885810:A:C	D509A	0.992
16:66885811:T:A	D509E	0.991
16:66885811:T:G	D509E	0.991
16:66884648:G:C	D122H	0.990
16:66885500:T:C	F406L	0.989
16:66885501:T:C	F406S	0.989
16:66885502:C:A	F406L	0.989
16:66885502:C:G	F406L	0.989
16:66885519:A:T	D412V	0.989
16:66885806:G:C	D508H	0.989
16:66884649:A:C	D122A	0.988
16:66885330:G:A	G349E	0.988
16:66885089:G:C	A269P	0.987
16:66885090:C:A	A269D	0.987
16:66885138:G:T	G285V	0.987
16:66885330:G:T	G349V	0.987
16:66885347:T:A	W355R	0.987
16:66885347:T:C	W355R	0.987
16:66885446:T:G	Y388D	0.987
16:66884997:T:C	L238P	0.986
16:66885323:G:C	A347P	0.986
16:66885804:G:T	R507M	0.986
16:66885808:T:A	D508E	0.986

dbSNP variants (sampled 300 via entrez): RS1000429102 (16:66882296 C>A,T), RS1000481657 (16:66882589 T>C), RS1000765762 (16:66883713 G>T), RS1000831915 (16:66891573 T>A), RS1000834913 (16:66883925 A>G), RS1000983156 (16:66883981 T>A), RS1001069878 (16:66891469 G>A), RS1001458185 (16:66884348 G>A), RS1001466115 (16:66890148 C>T), RS1001628288 (16:66883904 T>C), RS1001677229 (16:66883319 A>C,T), RS1002345302 (16:66890924 T>C), RS1002379756 (16:66891273 G>C), RS1002488152 (16:66883639 G>A,C,T), RS1003042784 (16:66887553 G>A)

Disease associations

OMIM: gene MIM:615499 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006630_74	Diastolic blood pressure	3.000000e-21
GCST010241_219	Apolipoprotein A1 levels	1.000000e-09
GCST010242_398	HDL cholesterol levels	7.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Leflunomide	decreases expression	2
Benzo(a)pyrene	decreases expression	2
Formaldehyde	decreases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Cyclosporine	decreases expression	2
sotorasib	decreases expression, affects cotreatment	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases methylation	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
butylbenzyl phthalate	increases expression	1
acipimox	increases expression	1
avobenzone	increases expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	decreases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Ampicillin	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cisplatin	decreases expression	1
Dexamethasone	increases expression	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TC85	HAP1 PDP2 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer